Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 142-146, 2008.
Artículo
en Coreano
| WPRIM
| ID: wpr-182743
ABSTRACT
Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Síndrome de Dificultad Respiratoria
/
Insuficiencia Respiratoria
/
Tórax
/
Carcinoma de Células Pequeñas
/
ADN-Topoisomerasas de Tipo I
/
Topotecan
/
Disnea
/
Carcinoma Pulmonar de Células Pequeñas
Límite:
Humanos
Idioma:
Coreano
Revista:
Tuberculosis and Respiratory Diseases
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS